Tech Company Financing Transactions
Xanthus Pharmaceuticals Funding Round
CDIB Bioscience, GeneChem and GIMV participated in a $25 million Series B funding round for Xanthus Pharmaceuticals. The funding round was announced on 12/1/2006.
Transaction Overview
Company Name
Announced On
12/1/2006
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Proceeds Purpose
Richard T. Dean,
Ph.D., Xanthus' Chief Executive Officer said, "With this financing, we believe Xanthus is wellpositioned
for the continued development of our pipeline of five oncology products."
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 5th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Dean
Chief Financial Officer
Robert Boisjoli
Chief Medical Officer
Robert Capizzi
Chief Operating Officer
Michael Boss
Chief Scientific Officer
Alfred Ajami
Vice President
John Lister-James
VP - Regulatory Affairs
Kris Piper
Browse more venture capital transactions:
Prev: 12/1/2006: BitTorrent venture capital transaction
Next: 12/1/2006: NextHop Technologies venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs